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Breast cancer accounted for 15 per cent of total cancer deaths in female patients in
2010. Although signiﬁcant progress has been made in treating early-stage breast cancer
patients, there is still no effective therapy targeting late-stage metastatic breast cancers
except for the conventional chemotherapy interventions. Until effective therapy for later-
stage cancers emerges, the identiﬁcation of biomarkers for the early detection of tumour
metastasis continues to hold the key to successful management of breast cancer therapy.
Our study concentrated on the low molecular weight (LMW) region of the serum
protein and the information it contains for identifying biomarkers that could reﬂect the
ongoing physiological state of all tissues. Owing to technical difﬁculties in harvesting
LMW species, studying these proteins/peptides has been challenging until now. In our
study, we have recently developed nanoporous chip-based technologies to separate small
proteins/peptides from the large proteins in serum. We used nanoporous silica chips,
with a highly periodic nanostructure and uniform pore size distribution, to isolate LMW
proteins and peptides from the serum of nude mice with MDA-MB-231 human breast
cancer lung metastasis. By matrix-assisted laser desorption/ionization time-of-ﬂight mass
spectrometry and biostatistical analysis, we were able to identify protein signatures
unique to different stages of cancer development. The approach and results reported in
this study possess a signiﬁcant potential for the discovery of proteomic biomarkers that
may signiﬁcantly enhance personalized medicine targeted at metastatic breast cancer.
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1. Introduction
Breast cancer is the most frequently occurring malignancy and the second
most frequent cause of cancer death in women in the USA and other Western
countries [1]. Signiﬁcant progress has been made on overall survival rates in breast
cancer. The 5 year overall survival rate of women diagnosed with stage I–III
breast cancer has been steadily improving for decades [2,3]. These improvements
in survival have primarily been attributed to the availability of modern diagnostic
tools that allow for early detection [4,5], and the increased use of adjuvant
systemic therapies [6,7]. However, improved states related to breast cancer
metastasis have been discouraging, with only marginal improvement in some
reports [2], to no marked improvement reported in other studies [3]i nt h e
survival rate of relapsed metastatic patients. The identiﬁcation of biomarkers
for the detection of cancer metastasis in the early stage may hold the key to the
management of metastatic breast cancer.
The process of metastasis can be divided into several steps, including the
detachment of tumour cells from the primary tumour, invasion, migration,
intravasation, survival in the vasculature, extravasation and colonization of the
secondary site [8]. There are also reports of circulating tumour cells that might
be responsible for tumour metastasis [9,10]. During the steps of metastasis, the
cancer tissue sheds cells and/or debris into the blood stream. Each cell leaves
behind proteins and peptides in the blood, either as waste or as signals to
neighbouring cells. These residual proteins and peptides may reveal new insights
into the evolution of the metastatic process.
If isolated and identiﬁed, proteomic biomarkers have the potential to revolu-
tionize the practice of medicine by providing the capability to diagnose disease
at a pre-symptomatic stage, closely tracking responses to therapy, in addition to
representing an important enabler to personalized medicine [11,12]. While there
is value in the ability to identify individual proteins that may act as single-
disease biomarkers, many diseases will more often be characterized by complicated
‘ﬁngerprints’ involving a number of proteins, peptides and fragments [13].
Although high molecular weight (HMW) proteins in blood have been extensively
studied, little is known about the composition of the low molecular weight
(LMW) proteins and peptides owing to the difﬁculties in isolation and puriﬁcation
of this population. These substances may circulate at very low levels and
are difﬁcult to detect in the presence of the abundance of proteins such as
albumin [14].
Biomolecules can now be identiﬁed via mass spectrometry (MS), yielding
a spectrum of the quantity of materials as a function of their molecule (and
molecular fragment) mass [15]. The ability to quantify all biomolecules, from very
large proteins down to peptides that comprise protein/peptide fragments as low as
a thousand daltons, is now emerging. Several technologies for sample fractionation
prior to MS analysis have been developed to address these limitations, including
conventional two-dimensional gel electrophoresis and beads equalization. In spite
of these advances, however, the detection of low abundance markers and small
proteins has remained a critical challenge owing to the labour-intensive and
low-throughput procedures, which have offered limited suitability for clinical
applications [16–18].
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In our study, we employed a mouse model of lung metastasis with the human
breast cancer cell line MDA-MB-231, which is a triple negative cell line lacking
expression of the oestrogen receptor (ER), the progesterone receptor (PR) and
the Her2 receptor (HER2). The lung is one of the most frequent sites of breast
cancer metastasis. Approximately, 60 per cent of breast cancer patients have had
cancer cells eventually spread to their lungs. In 21 per cent of all cases, the lung
is the only metastatic organ [19]. Triple negative breast cancer primarily affects
younger women (atypical for breast cancer in general), women with African–
American descent and women carrying a BRCA1 mutation [20]. Its aggressive
nature and high rate of reoccurrence, as well as this cancer’s resistance to
common targeted therapies, are attributed to the lack of ER, PR and HER2.
Patients in this subgroup must revert to conventional cytotoxic chemotherapy,
such as anthracycline and taxane, and endure the substantial burden of adverse
effects. While conventional chemotherapy and radiation therapy are initially
effective in controlling breast cancer growth, patients frequently relapse over
time. We have developed nanoporous silica chips to capture LMW serum
peptides and proteins [21–26]. In our study, we used nanoporous silica chips
to isolate LMW proteins and peptides from the serum of MDA-MB-231 lung
metastatic cancer mice. Matrix-assisted laser desorption/ionization time-of-ﬂight
mass spectrometry (MALDI-TOF MS) was used in proﬁling the serum samples
in three distinct groups (control, early stage and late stage). All data were then
subjected to principal component analysis (PCA) and vertical scatter plots were
drawn to identify signatures unique to the different stages of cancer development.
2. Experimental
(a) Fabrication of nanoporous silica thin ﬁlms
A typical preparation of the coating sol is as follows. Fourteen millilitres
of tetraethyl orthosilicate (TEOS; Sigma-Aldrich, St. Louis, MO, USA) was
dissolved in a mixture of 17ml of ethanol, 6.5ml of distilled water and 0.5ml of
2M HCl and stirred for 1h at 80◦C to form a clear silicate solution. Separately,
1.8g of Pluronic F-127 (BASF Co.) was dissolved in 10ml of ethanol by stirring
at room temperature. The coating solution was prepared by mixing the silicate
solution into the triblock copolymer solution followed by stirring of the resulting
solution for 2h at room temperature. The pH of the mixture solution remained
around 1.5. The coating sol was deposited on a Si (100) wafer by spin-coating at
the spin rate of 2000 r.p.m. for 20s. To increase the degree of polymerization of
the silica framework in the ﬁlms and to further improve their thermal stability,
the ﬁlms were heated at 80◦C for 12h. They were then calcinated at 425◦Ct o
remove the organic surfactant. The temperature was raised at a rate of 1◦C min−1,
and the furnace was heated at 425◦C for 5h.
(b) Characterization techniques
We used several characterization techniques to study the spin-coated,
nanoporous silica thin ﬁlms. By employing a variable-angle spectroscopic
ellipsometer (J. A. Woollam Co., M-2000DI) and modelling with COMPLETEEASE
software, the thickness of the thin ﬁlms and their porosities were measured
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in the Cauchy model and effective medium approximation (EMA) model,
respectively. Ellipsometric optical quantities, the phase (D) and amplitude (j),
were determined by acquiring spectra at 60◦,6 5 ◦ and 70◦ incidence angles using
wavelengths from 300 to 1800nm. In the Cauchy model, the top layer’s thickness,
reﬂective index and model-ﬁtted, parameters An, Bn and Cn were determined
by comparing the experimental data with the model and minimizing the mean
square error (usually less than 10). Using the EMA model, the ﬁlms’ porosities
were calculated by assuming a certain volume of voids in the pure silica and
setting the top layer’s thickness obtained by the Cauchy model as a constant.
X-ray diffraction (XRD) patterns were obtained on a Philips X’Pert-MPD system
with Cu Ka radiation (45kV, 40mA). Scans of q–2q were recorded from all
spin-coated ﬁlms at 1s and 0.001◦ steps over the angle range from 0.2◦ to 6◦.
Transmission electron microscopy (TEM) and scanning transmission electron
microscopy (STEM) were used to acquire micrographs of the plane view of
nanoporous silica thin ﬁlms with an FEI Technai (FEI Co.) at a high tension of
200kV. Ellipsometric porosimetry (Semilab Semiconductor Physics Laboratory
Co. Ltd.) was applied to measure the adsorption/desorption isotherm and pore
size distribution. Nanopore size distributions were calculated from the desorption
branch of the isotherms using the Barrett–Joyner–Halenda (BJH) method. A
Nicolet Magna 560 spectrometer was used in the transmission mode for Fourier
transform infrared (FTIR) measurements, with wavenumber resolution at 4cm−1,
256 scans and the wavenumber range approximately 4000–520cm−1. During
measurements, the FTIR chamber was purged with N2 gas to remove water
vapour and carbon dioxide.
(c) Construction of bioluminescent breast cancer cell line
The oestrogen-independent human breast cancer cell line MDA-MB-231 was
purchased from the American Type Culture Collection (ATCC), and cultured
in high-glucose Dulbecco’s modiﬁed Eagle’s Minimal Essential Medium (DMEM;
Invitrogen, Grand Island, NY, USA), which contains 10 per cent foetal bovine
serum (FBS; Atlanta Biologicals, Lawrenceville, GA, USA) and 1 per cent
penicillin–streptomycin solution (Life Technologies, Inc., Grand Island, NY,
USA), in a humidiﬁed atmosphere of 5 per cent CO2 in air at 37◦C. The
process of constructing the bioluminescent cell line has been published before [27].
Brieﬂy, the ﬁreﬂy luciferase gene (luc2; Promega, Madison, WI, USA) was ﬁrst
cloned into the pcDNA6.2-GFP-DEST vector (Invitrogen) to obtain the fused
luciferase/GFP cassette. After puriﬁcation, the cassette was cloned to a lentivirus
backbone (Invitrogen) to form an engineered plasmid and then packaged into
virus particles. After transfection with these virus particles, GFP-positive MDA-
MB-231 cells were selected by ﬂuorescence-activated cell sorting. Cells were
maintained in complete DMEM with 6mgml
−1 blasticidin.
(d) Animal model
All animal work was done in accordance with a protocol approved by the
Institutional Animal Care and Use Committee (IACUC) of The Methodist
Hospital Research Institute in Houston, TX, USA. Eight-week-old female nude
mice were purchased from Charles River Laboratories (Boston, MA, USA). They
were housed in a speciﬁc pathogen-free facility under a 12h light–12h dark cycle,
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and fed with a pathogen-free diet and water ad libitum. To constitute a mouse
model of breast cancer lung metastasis (BCLM), 3 × 105 MDA-MB-231/luciferase
cells were washed and suspended in phosphate buffer solution (PBS), and
subsequently injected into the lateral tail vein in a volume of 100ml. The mice were
imaged weekly after tumour cell inoculation. Prior to imaging, the mice were ﬁrst
anaesthetized with isoﬂorane. They were then treated by intraperitoneal injection
of D-luciferin (150mgkg
−1 body weight in PBS; Caliper Lifesciences, Hopkinton,
MA, USA), and placed onto a warmed stage inside the light-tight chamber of
an IVIS Imaging System 200 series (Xenogen, Alameda, CA, USA). In order
to collect consistent and the strongest possible bioluminescence, all images were
captured by the IVIS system 10min after luciferin. A semiquantitative region of
interest (ROI) analysis was performed with the LIVE IMAGE v. 4.2 software, and
the intensity of bioluminescence was used as the parameter to measure growth
and to rank the stages of lung metastasis.
(e) On-chip sample fractionation
After collecting whole blood samples from the mice, the samples were allowed
to clot at room temperature in microcentrifuge tubes (Eppendorf, USA) for
1h. The samples were centrifuged twice at 3000 r.p.m. for 15min. The separated
serum was then removed with a pipette and placed in aliquots of 40ml in new
microcentrifuge tubes. The serum samples were stored at −80◦C until used, while
the remaining components of the mouse blood were discarded. Pretreatment
of the samples began with thawing the serum samples on ice. A pretreatment
solution of 50 per cent acetonitrile (ACN; Sigma-Aldrich, St. Louis, MO, USA)
and 0.1 per cent triﬂuoroacetic acid (TFA; Sigma-Aldrich, St. Louis, MO, USA) in
deionized water was prepared and vortex-mixed. This pretreatment solution was
added to the thawed serum samples in a 1:9 ratio to obtain ﬁnal concentrations
of ACN and TFA of 5 and 0.01 per cent, respectively. The samples were then
mixed on a table vortexer at room temperature for 30min.
After mixing, the samples were again spun in a centrifuge, this time at 5000
r.p.m. for 5min. Meanwhile, the porous silica chips were ﬁrst baked in an oven at
160◦C overnight. Compressed air was used to remove any dust from the surface.
Chambered coverslips (Sigma-Aldrich, St. Louis, MO, USA) were washed with
100 per cent ethanol and cut to size. They were placed on the chip surface and
secured using forceps to ensure complete adherence to the chip. Five microlitres of
each sample were pipetted into each well, ensuring that no precipitate in the base
of a tube was placed on the chip. The samples were allowed to incubate at room
temperature in a 100 per cent humidiﬁed chamber for 30min. The serum samples
were pipetted up from the well and discarded. Each well was washed four times
with 10ml of deionized water. The elution buffer was the same as the pretreatment
solution (50% ACN and 0.1% TFA in deionized water). Five microlitres of elution
buffer were applied to each well and mixed by pipette, up and down 30 times,
while rotating the pipette tip around in a random manner. Finally, the elution
buffers were pipetted up and placed in new microcentrifuge tubes. These tubes
were then stored at −80◦C until ready for MALDI-TOF analysis.
(f) Matrix-assisted laser desorption/ionization time-of-ﬂight analysis
The samples from the chips were removed from the freezer and allowed to
thaw on ice. Then 0.5ml of each sample was spotted on the MALDI target plate
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and allowed to dry completely; and 0.5ml of the matrix solution was spotted
on the target plate and allowed to dry. We used a matrix solution of 5gl
−1 of
a-cyano-4-hydroxycinnamic acid (CHCA) in 50 per cent ACN and 0.1 per cent
TFA. Mass spectra were acquired using the Applied Biosystems 4700 MALDI
TOF/TOF Analyzer (Applied Biosystems, Inc., Framingham, MA, USA) at the
M.D. Anderson Cancer Center, Houston, TX, USA. Samples were analysed using
positive reﬂector mode (laser intensity 4200, 3000 shots/sample and mass range
800–5000 Da with target mass of 2000 Da).
(g) Statistical analysis
The resultant MALDI-TOF data were processed using CONVERTPEAKLIST
software to generate text ﬁles, listed in mass–intensity pairs. These text ﬁles were
then imported into SPECALIGN software for visualization and average spectrum
generation. The PCA and t-test analysis were performed by MARKERVIEW
software v. 1.2.1 (AB SCIEX, Concord, Canada). Six repeated spectra for each
sample were selected and imported into MARKERVIEW. The data were normalized
to total area sum. PCA processing was carried out with a Pareto scaling. The
t-value and corresponding p-value were also calculated using MARKERVIEW
between BCLM and the control groups.
3. Results and discussion
With the speciﬁed molar ratio (1:0.006) of silicate to F-127 copolymer
designed in this study, the ﬁnal product yielded a three-dimensional honeycomb-
like nanostructure hexagonally arranged on the substrate, as depicted in
its STEM plane view at low magniﬁcation (ﬁgure 1a) and its TEM plane
view at high magniﬁcation (ﬁgure 1b). The XRD plot (ﬁgure 1c) represents
the pattern of a thin ﬁlm, also conﬁrmed as a hexagonal nanostructure
with the appearance of a high-intensity (100) reﬂection peak at 2q =
1.026◦ (d100 =8.604nm) and a lower-intensity peak at (210) with d210 =
4.600nm. After high-temperature calcination treatment, an oxygen plasma
was applied to restore the defective points (Si–H) on the nanoporous silica
surface and generated high-density Si–OH groups as shown by the FTIR
pattern (ﬁgure 1d), providing bonding conﬁguration characterization and the
molecular structure of the speciﬁc groups within the porous framework.
The peak at 793cm−1 represents various molecular species, including Si–
OH, Si–OH–OH2 and Si–CH–O. In addition, the peak at 1074cm−1 indicates
that the silica networks comprise Si–O–Si backbones. The FTIR results
indicate that the silica surface afﬁnity constitutes an advantage in the
enrichment of LMW proteins. The adsorption/desorption isotherms (ﬁgure
1e) signal an H1 hysteresis loop attributed to cylindrically shaped pores
(sloping adsorption branch and nearly vertical desorption branch), indicating
a nanoporous structure with opened interconnecting channels. As depicted in
ﬁgure 1f, the pore size distributions on the ﬁlms display a symmetric and sharp
single peak, at a pore diameter of 3.72nm from the adsorption curve, which
strongly points to a silica framework with uniform nanotexture distribution.
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Figure 1. The physical characterization of nanoporous silica thin ﬁlms: (a) STEM plane view
of nanoporous silica ﬁlm; (b) TEM plane view; (c) XRD pattern; (d) FTIR spectrum;
(e) adsorption/desorption isotherm; and (f) pore size distribution. (Online version in colour.)
We generated mouse models of BCLM with MDA-MB-231 human breast
cancer cells. These cancer cells were engineered with an overexpression of the
luciferase gene. Tumour growth was monitored in live animals by the increase in
bioluminescence after injection of D-luciferin into the intraperitoneal cavity. The
luciferase enzyme in cancer cells digested D-luciferase, and turned this otherwise
non-ﬂuorescent substrate into a strongly ﬂuorescent dye. After inoculation with
3 million cells per mouse, we measured an increase of bioluminescence throughout
the next 8–10 weeks (ﬁgure 2). Most mice would die of tumour growth in the
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Figure 2. Imaging of MDA-MB-231 tumour growth in nude mice. The MDA-MB-231 human
breast cancer cells were engineered with a luciferase gene. Tumour growth was monitored by
bioluminescent intensity with a Xenogen IVIS 200 imaging system. The areas of lung tumour
are shown boxed, and quantitation of bioluminescent intensity is summarized in table 1. (Online
version in colour.)
lung after 10 weeks. We arbitrarily divided the tumour mice into early-stage
breast cancer lung metastasis (BCLM-ES) tumour and late-stage breast cancer
lung metastasis (BCLM-LS) tumour groups, based on bioluminescent intensity
(ﬁgure 2), and collected blood by retro-orbital bleeding for proteomic analysis
to identify biomarkers that reﬂect changes in tumour progression. Samples from
the BCLM-ES mice were collected two to three weeks post-tumour inoculation,
and those from the BCLM-LS tumour mice were taken four weeks later. The
growth of metastatic tumours can be judged by the six- to ninefold increase of
bioluminescent intensity between the early-stage and late-stage tumours (table
1). We also collected blood samples from normal nude mice as negative controls.
There were eight animals per group in this experiment.
The schematic for serum fractionation using the mesoporous silica (MPS)
thin ﬁlms is shown in ﬁgure 3. After 30min of pretreatment with 5 per cent
ACN and 0.01 per cent TFA, 7ml of the serum sample was added to each well
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m/z
Figure 3. Schematic of enrichment of LMW proteins and peptides on a nanochip. (a) A unit on
a nanoporous silica chip for sample processing. (b) After sample spotting on the surface, LMW
proteins and peptides were trapped in the pores, while the larger species remained outside the
pores. (c) These were removed during the washing steps. (d) Enriched fractions were eluted and
analysed by MALDI. (Online version in colour.)
Table 1. Bioluminescent intensity of tumours in nude mice.
bioluminescent intensity (×104)
group mouse no. 1 mouse no. 2 mouse no. 3
control 7.33 2.08 7.12
early-stage tumour 69.2 31.6 37.1
late-stage tumour 434 191 305
on the MPS thin ﬁlm surface and incubated for 30min in a humidiﬁed box.
The LMW proteins and peptides were loaded into the nanopores, while large
proteins, such as albumin, immunoglobulin G, etc., were removed by washing the
nanochip surface several times with deionized water. The enriched LMW proteins
and peptides were eluted with 5ml of 50 per cent ACN and 0.1 per cent TFA.
These eluted samples were analysed with MALDI-TOF MS to obtain proﬁles
of the LMW proteins and peptides in mouse serum from all three groups. The
peptides in mouse serum were enriched and could be detected by MALDI-TOF
MS. Furthermore, the average spectrum appeared widely different in the low-
mass range (800–3000Da) between the control and the tumour groups based on
their MALDI-TOF MS spectra (ﬁgure 4).
For statistical analysis of the proﬁles for LMW proteins and peptides acquired
after processing on nanochips, we applied PCA using MARKERVIEW. PCA is a
statistical procedure commonly used for reducing dimensional variables, while
still maintaining most of the original series [28]. For PCA analysis, the ﬁrst
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Figure 4. The average MALDI-TOF mass spectrum of mice serum between (a) normal control and
(b) BCLM groups. Mass spectra obtained after serum samples were processed on F-127 nanochip.
The 1243.7 and 1259.7 Da peaks were downregulated in (a), and the 1378.8, 1479.8, 1580.9, 1853.9,
2010.1 and 2081.1 Da peaks were upregulated in (b). (Online version in colour.)
principal component (PC1) and the second principal component (PC2) determine
the ﬁrst and the second greatest amounts of variance. After PCA processing using
MARKERVIEW, the principal components (PCs) were calculated and plotted for
each sample score PC1 and PC2, as shown in ﬁgure 5a. In this study, for the
BCLM-LS and control groups, PC1 yielded 52.9 per cent of the variance, and
PC2 12.8 per cent. The score plot of PC1/PC2 indicates that the BCLM-LS
group was completely separated from the control group based on their PC1
score. The control group (right-hand cluster, green symbols) received positive
PC1 scores, while the BCLM-LS group (left-hand cluster, red symbols) attained
negative scores. Therefore, PCA analysis suggests that potential exists for using
the LMW protein and peptide proﬁles obtained after processing on a nanochip
as a diagnostic tool for distinguishing between tumour and non-tumour groups.
The results for early-stage (BCLM-ES) samples compared with the control group
were also analysed with PCA procedures, as shown in ﬁgure 5b. Slightly different
from the proﬁling of BCLM-LS, the BCLM-ES samples (left-hand and upper
clusters, blue symbols) received both positive and negative PC1 scores, but could
still be separated from the control group based on PC score, indicating that
nanoporous chip-based technology provides a potential pathway for biomarker
discovery for early-stage metastatic breast cancer. The loadings plot in ﬁgure 5c
demonstrates the PC1 and PC2 loadings for each variable, indicating how each
variable contributes to the PCs. In other words, the PC loading plots reveal
peptides that can be used to speciﬁcally distinguish between different groups.
The peptides with the larger PC loadings are the more important variable and
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Figure 5. PCA analysis of control, BCLM-LS and BCLM-ES groups. PC1 and PC2 scores obtained
through PCA analysis of the replicated MALDI-TOF MS datasets in three groups. (a) The scores
plot of PC1/PC2 between the BCLM-LS and control groups. (b) The scores plot of PC1/PC2
between the BCLM-ES and control groups. (c) The loadings plot speciﬁc for PC1/PC2 between the
BCLM-LS and control groups. Highlighted ion clusters represent speciﬁc peptides for classiﬁcation
within these two groups. (Online version in colour.)
thus have more potential as diagnostic biomarkers for classifying tumour and non-
tumour groups. The peptide points with the higher loadings are highlighted (red
ellipses) in ﬁgure 5c.
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Figure 6. Different expressed biomarker candidates between the normal control group and the
breast cancer lung metastasis groups in mice serum. Eight biomarker candidates were detected.
Signiﬁcance: ∗p <0.05; ∗∗p <0.01. (Online version in colour.)
To examine the speciﬁc peptides revealed by the loadings plot, a t-test
analysis was performed using MARKERVIEW. The t-test was carried out by
comparing each group to the remaining two groups, to determine how the variable
distinguished these three sets. The peptides highlighted in the loadings plot
showed low p-value between the control group and the BCLM-LS group, which
indicated good agreement with PCA analysis. The vertical scatter plots of eight
speciﬁc biomarkers shown in ﬁgure 6 exhibit the variable expressed level of the
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speciﬁc LMW proteins or peptides during the three different stages of breast
cancer lung metastasis. Peptides at m/z =1243 and 1259 Da were signiﬁcantly
downregulated in both BCLM-ES and BCLM-LS groups at the early and late
stage of BCLM in order to compare with the control group. The other six
peptides, at m/z =1378, 1479, 1580, 1853, 2010 and 2081 Da, respectively, were
signiﬁcantly upregulated in BCLM-ES and BCLM-LS groups, except for the
peptide at 1853 Da in the BCLM-ES group, which exhibited the same level as
in our control group. The level of fragments at m/z =1243 and 1259 Da was
signiﬁcantly downregulated in the control group mice compared to both early-
stage and late-stage tumour mice. The level of the ﬁve fragments at m/z =1378,
1479, 1580, 2010 and 2081 Da was signiﬁcantly upregulated in both groups of mice
with tumours.
It is interesting to note that the candidate biomarkers can be divided into
three groups (ﬁgure 6). Group 1 fragments include 1243, 1259, 1378 and 1580;
fragment 1853 is the only member in group 2; and group 3 fragments are 1479,
2081 and 2010. Changes in serum level of group 1 fragments could be detected in
both BCLM-ES and BCLM-LS mice. These fragments can serve as biomarkers
for detection of early-stage tumour metastasis, as elevated levels of the fragments
could be detected in mouse serum as early as two weeks after tumour inoculation.
A similar basal level of fragment 1853 could be detected in control mice and
BCLM-ES mice, but the level is signiﬁcantly elevated in BCLM-LS mice. This
fragment is indicative of late-stage tumours. The level of group 3 fragments
increased during tumour development, and reached a peak in BCLM-LS mice.
Analysis of expression signatures based on the mass spectrum could thus be used
to determine which stage of cancer development a patient is in. Application of
biomarker analysis in the clinic could guide physicians to treat cancer patients
better based on their disease progression. These expression signatures can also
serve as biomarkers to monitor therapeutic efﬁcacy for patients under drug
treatment. For example, the trend of group 3 markers may very well be reversed
if the tumour mice were treated with chemotherapy or targeted therapy drugs.
More detailed studies in mass sequence are needed to validate the usefulness of
these biomarkers.
4. Conclusion
Nanoporous silica chips are very efﬁcient in capturing LMW proteins and peptides
from the serum of mouse models of human breast cancers. Once isolated,
small proteins and peptides in this study have unique levels of expression for
different stages of BCLM. Further characterization studies of these proteins
and peptides will identify even better the biomarkers that are indicative of
cancer development. Thus, the nanotechnology-based silica chips provide a rapid,
sensitive, reproducible and inexpensive platform that will lead to signiﬁcant,
personalized diagnosis and new therapies for the treatment of breast cancer.
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